Cerevel Therapeutics Holdings, Inc. Stock
Equities
CERE
US15678U1280
Biotechnology & Medical Research
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
41.64 USD | +0.79% | -1.10% | -1.78% |
Mar. 25 | Actinogen Medical Notifies of Errors on M&A Slide in Recent Presentation | MT |
Mar. 04 | Cerevel Therapeutics Holdings Insider Sold Shares Worth $2,057,890, According to a Recent SEC Filing | MT |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 7.5B |
---|---|---|---|---|---|
Net income 2024 * | -456M | Net income 2025 * | -551M | EV / Sales 2024 * | - |
Net cash position 2024 * | 709M | Net cash position 2025 * | 690M | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-16.6
x | P/E ratio 2025 * |
-14.8
x | Employees | 334 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 42.24% |
Latest transcript on Cerevel Therapeutics Holdings, Inc.
1 day | +0.80% | ||
1 week | -1.16% | ||
Current month | -1.54% | ||
1 month | -2.21% | ||
3 months | -1.44% | ||
6 months | +83.11% | ||
Current year | -1.84% |
Managers | Title | Age | Since |
---|---|---|---|
Ronald Renaud
CEO | Chief Executive Officer | 55 | 23-06-11 |
Director of Finance/CFO | 43 | 23-05-14 | |
N. Coles
CHM | Chairman | 63 | 18-11-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 63 | 19-05-31 | |
Douglas Giordano
BRD | Director/Board Member | 61 | 18-08-31 |
Ruth McKernan
BRD | Director/Board Member | 66 | 20-12-03 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.10% | 2 M€ | -.--% |
Date | Price | Change | Volume |
---|---|---|---|
24-04-17 | 41.62 | +0.74% | 481 619 |
24-04-16 | 41.31 | -0.94% | 1,439,526 |
24-04-15 | 41.7 | -0.36% | 1,333,538 |
24-04-12 | 41.85 | -0.38% | 2,259,340 |
24-04-11 | 42.01 | -0.24% | 948,569 |
Delayed Quote Nasdaq, April 17, 2024 at 02:18 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-1.84% | 7.5B | |
-3.24% | 102B | |
+3.18% | 96.09B | |
-1.02% | 22.05B | |
-17.94% | 20.81B | |
-6.87% | 19.06B | |
-40.70% | 16.05B | |
-26.22% | 14.01B | |
+1.65% | 13.38B | |
+22.50% | 11.01B |
- Stock Market
- Equities
- CERE Stock